Jury Clears Endo in First Testosterone Trial

Nov 19, 2017

Reuters

A federal jury ruled that Endo International’s Auxilium unit was not liable for causing Steve Holtsclaw of Tennessee to have a heart attack while taking its testosterone replacement drug Testim, according to a Reuters article. Holtsclaw was hospitalized twice, but has since recovered.

The verdict was a big win for the manufacturer in its first trial over allegations its Testim skin gel had design defects, and that the company misrepresented its risks. Endo and its subsidiaries face about 1,290 other Testim lawsuits in courts across the country, the story said.

The case is part of a larger litigation as up to 6,000 plaintiffs allege that many defendants, such as AbbVie, Pfizer, Endo Pharmaceuticals and GlaxoSmithKline all failed to properly warn patients about the cardiovascular risks from their testosterone drugs.

Read the full article